<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04518995</url>
  </required_header>
  <id_info>
    <org_study_id>CP543.3001</org_study_id>
    <secondary_id>2020-002704-40</secondary_id>
    <nct_id>NCT04518995</nct_id>
  </id_info>
  <brief_title>A Phase 3 Study to Evaluate the Efficacy and Safety of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata (THRIVE-AA1)</brief_title>
  <acronym>THRIVE-AA1</acronym>
  <official_title>A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Concert Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Concert Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center Phase 3 study to evaluate the safety and effectiveness of an&#xD;
      investigational study drug (called CTP-543) in adults (18 years and older) who have 50% or&#xD;
      greater scalp hair loss. The study is placebo-controlled, meaning that some patients entering&#xD;
      the study will not receive active study drug but will receive tablets with no active&#xD;
      ingredients (a placebo). It is double-blinded, meaning that the Sponsor, the study doctors,&#xD;
      the staff, and the patients will not know whether a patient is on active study drug (or the&#xD;
      dose) or placebo.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 2, 2020</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients achieving an absolute Severity of Alopecia Tool (SALT) score ≤20</measure>
    <time_frame>Week 24</time_frame>
    <description>SALT is a quantitative assessment of scalp hair loss with scores ranging from 0 (no scalp hair loss) to 100 (complete scalp hair loss).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of responders (defined as &quot;satisfied&quot; or &quot;very satisfied&quot;) on the Hair Satisfaction Patient Reported Outcome (SPRO)</measure>
    <time_frame>Week 24</time_frame>
    <description>SPRO is a questionnaire answered by the patient designed to measure how satisfied alopecia areata patients are with their hair at the time of the assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients achieving an absolute SALT score of ≤20</measure>
    <time_frame>Weeks 12, 16, and 20</time_frame>
    <description>SALT is a quantitative assessment of scalp hair loss with scores ranging from 0 (no scalp hair loss) to 100 (complete scalp hair loss).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative change in SALT scores from Baseline</measure>
    <time_frame>Weeks 4, 8, 12, 16, 20, and 24</time_frame>
    <description>SALT is a quantitative assessment of scalp hair loss with scores ranging from 0 (no scalp hair loss) to 100 (complete scalp hair loss).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of responders (defined as &quot;much improved&quot; or &quot;very much improved&quot;) using the CGI-I</measure>
    <time_frame>Weeks 12, 16, 20, and 24</time_frame>
    <description>The Clinician Global Impression of Improvement (CGI-I) is a questionnaire that asks the clinician to evaluate the improvement or worsening of the patient's alopecia areata as compared to the start of the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of responders (defined as &quot;much improved&quot; or &quot;very much improved&quot;) using the PGI-I</measure>
    <time_frame>Weeks 12, 16, 20, and 24</time_frame>
    <description>The Patient Global Impression of Improvement (PGI-I) is a self-administered questionnaire that asks the patient to evaluate the improvement or worsening of their alopecia areata as compared to the start of the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the CGI-S</measure>
    <time_frame>Weeks 12, 16, 20, and 24</time_frame>
    <description>The Clinician Global Impression of Severity (CGI-S) is a questionnaire that asks the clinician to evaluate the severity of the patient's alopecia areata at the time of assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the PGI-S</measure>
    <time_frame>Weeks 12, 16, 20, and 24</time_frame>
    <description>The Patient Global Impression of Severity (PGI-S) is a self-administered questionnaire that asks the patient to evaluate the severity of their alopecia areata at the time of assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients achieving at least a 75% relative reduction in SALT score from Baseline</measure>
    <time_frame>Weeks 12 and 24</time_frame>
    <description>SALT is a quantitative assessment of scalp hair loss with scores ranging from 0 (no scalp hair loss) to 100 (complete scalp hair loss).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients achieving at least a 90% relative reduction in SALT score from Baseline</measure>
    <time_frame>Weeks 12 and 24</time_frame>
    <description>SALT is a quantitative assessment of scalp hair loss with scores ranging from 0 (no scalp hair loss) to 100 (complete scalp hair loss).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline on an eyebrow score</measure>
    <time_frame>Weeks 12 and 24</time_frame>
    <description>A clinician-rated scale that assesses the total eyebrow hair present. The score is derived by assessment of density and surface area of the patient's eyebrows.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline on an eyelash score</measure>
    <time_frame>Weeks 12 and 24</time_frame>
    <description>A clinician-rated scale that assesses the total eyelash hair present. The score is derived by assessment of density and distribution of the patient's eyelashes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of responders (defined as &quot;satisfied&quot; or &quot;very satisfied&quot;) on the Hair Satisfaction Patient Reported Outcome scale</measure>
    <time_frame>Weeks 12, 16, and 20</time_frame>
    <description>SPRO is a questionnaire answered by the patient designed to measure how satisfied alopecia areata patients are with their hair at the time of the assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline on the individual items of the Hair Quality Patient Reported Outcome (QPRO) scale</measure>
    <time_frame>Weeks 12, 16, 20, and 24</time_frame>
    <description>The QPRO questionnaire provides additional details on key attributes of hair and helps provide context to the SPRO response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the depression scale of the Hospital Anxiety and Depression Scale (HADS)</measure>
    <time_frame>Week 24</time_frame>
    <description>HADS is a 14-item measure designed to assess anxiety and depression symptoms in medical patients. Items are rated on a 4-point severity scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the anxiety scale of the Hospital Anxiety and Depression Scale</measure>
    <time_frame>Week 24</time_frame>
    <description>HADS is a 14-item measure designed to assess anxiety and depression symptoms in medical patients. Items are rated on a 4-point severity scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients achieving an absolute SALT score of ≤10</measure>
    <time_frame>Week 24</time_frame>
    <description>SALT is a quantitative assessment of scalp hair loss with scores ranging from 0 (no scalp hair loss) to 100 (complete scalp hair loss).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">708</enrollment>
  <condition>Alopecia Areata</condition>
  <arm_group>
    <arm_group_label>CTP-543, 8 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral tablet for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CTP-543, 12 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral tablet for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, BID</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral tablet for 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CTP-543, 8 mg BID</intervention_name>
    <description>8 mg twice-daily (BID)</description>
    <arm_group_label>CTP-543, 8 mg BID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CTP-543, 12 mg BID</intervention_name>
    <description>12 mg twice-daily (BID)</description>
    <arm_group_label>CTP-543, 12 mg BID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo, BID</intervention_name>
    <description>Placebo, twice-daily (BID)</description>
    <arm_group_label>Placebo, BID</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinical presentation compatible with alopecia areata with a current episode lasting&#xD;
             at least 6 months and not exceeding 10 years at the time of Screening. Total disease&#xD;
             duration greater than 10 years is permitted.&#xD;
&#xD;
          -  At least 50% scalp hair loss, as defined by a SALT score ≥50, at Screening and&#xD;
             Baseline.&#xD;
&#xD;
          -  Willing to comply with the study visits and requirements of the study protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Treatment with other medications or agents within 1 month of Baseline or during the&#xD;
             study that may affect hair regrowth or immune response.&#xD;
&#xD;
          -  Active scalp inflammation, psoriasis, or seborrheic dermatitis requiring topical&#xD;
             treatment to the scalp, significant trauma to the scalp, or other scalp condition that&#xD;
             may interfere with the SALT assessment, or untreated actinic keratosis anywhere on the&#xD;
             body at Screening and/or Baseline.&#xD;
&#xD;
          -  Treatment with systemic immunosuppressive medications within 3 months of Screening or&#xD;
             during the study, or biologics within 6 months of Screening or during the study.&#xD;
&#xD;
          -  Females who are nursing, pregnant, or planning to become pregnant while in the study,&#xD;
             and for 30 days after last dose of study drug.&#xD;
&#xD;
          -  Clinically significant medical condition, psychiatric disease, or social condition, as&#xD;
             determined by the Investigator, that may unfavorably alter the risk-benefit of study&#xD;
             participation, adversely affect study compliance, or confound interpretation of study&#xD;
             results.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Total Skin and Beauty Dermatology Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kern Research, Inc.</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Dermatology &amp; Clinical Research Institute</name>
      <address>
        <city>Encinitas</city>
        <state>California</state>
        <zip>92024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UC Irvine Dermatology Clinical Research Center</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92697</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Quest Dermatology Research</name>
      <address>
        <city>Northridge</city>
        <state>California</state>
        <zip>91324</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente South Sacramento</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95823</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Colorado Center for Dermatology and Skin Surgery</name>
      <address>
        <city>Centennial</city>
        <state>Colorado</state>
        <zip>80111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Colorado Medical Research Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University, Church Street Research Unit</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lenus Research &amp; Medical Group, LLC</name>
      <address>
        <city>Sweetwater</city>
        <state>Florida</state>
        <zip>33172</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Trials of Florida, Inc.</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forward Clinical Trials Inc.</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33624</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Denova Research</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern Memorial Hospital, Department of Dermatology</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dawes Fretzin Clinical Research Group, LLC</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46250</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DS Research</name>
      <address>
        <city>New Albany</city>
        <state>Indiana</state>
        <zip>47150</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Indiana Clinical Trials Center, PC</name>
      <address>
        <city>Plainfield</city>
        <state>Indiana</state>
        <zip>46168</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DS Research</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40241</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Qualmedica Research LLC</name>
      <address>
        <city>Owensboro</city>
        <state>Kentucky</state>
        <zip>42301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital - Clinic</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clarkston Skin Research</name>
      <address>
        <city>Clarkston</city>
        <state>Michigan</state>
        <zip>48346</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minnesota Clinical Study Center</name>
      <address>
        <city>Fridley</city>
        <state>Minnesota</state>
        <zip>55432</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota Department of Dermatology</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55417</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skin Laser and Surgery Specialists of NJ</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sadick Research Group</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10075</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Darst Dermatology</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28277</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Specialists of Charlotte</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28277</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Health Sciences, Department of Dermatology</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bexley Dermatology Research</name>
      <address>
        <city>Bexley</city>
        <state>Ohio</state>
        <zip>43209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vital Prospects Clinical Research Institute, P.C.</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Dermatology Institute</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Associates Of Plymouth Meeting</name>
      <address>
        <city>Plymouth Meeting</city>
        <state>Pennsylvania</state>
        <zip>19462</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PEAK Research</name>
      <address>
        <city>Upper Saint Clair</city>
        <state>Pennsylvania</state>
        <zip>15241</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Center of the Carolinas</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palmetto Clinical Trial Services</name>
      <address>
        <city>Fountain Inn</city>
        <state>South Carolina</state>
        <zip>29644</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bellaire Dermatology Associates</name>
      <address>
        <city>Bellaire</city>
        <state>Texas</state>
        <zip>77401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Treatment and Research Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austin Institute for Clinical Research, Inc.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77056</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austin Institute for Clinical Research, Inc.</name>
      <address>
        <city>Pflugerville</city>
        <state>Texas</state>
        <zip>78660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Clinical Research Center of San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West End Dermatology Associates</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Investigation Specialists, Inc.</name>
      <address>
        <city>Kenosha</city>
        <state>Wisconsin</state>
        <zip>53144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Research Institute</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T1Y 0B4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kirk Barber Research</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2G 1B1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Enverus Medical Research</name>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <zip>V3V 0C6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wiseman Dermatology Research Inc.</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3M 3Z4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SimcoDerm Medical and Surgical Dermatology Center</name>
      <address>
        <city>Barrie</city>
        <state>Ontario</state>
        <zip>L4M 7G1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guelph Dermatology Research</name>
      <address>
        <city>Guelph</city>
        <state>Ontario</state>
        <zip>N1L 0B7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr Wei Jing Loo Medicine Professional Corporation</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6H 5L5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lynderm Research Inc.</name>
      <address>
        <city>Markham</city>
        <state>Ontario</state>
        <zip>L3P 1X2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. S. K. Siddha Medicine Professional Corporation</name>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <zip>L3Y 5G8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Centre for Clinical Trials</name>
      <address>
        <city>Oakville</city>
        <state>Ontario</state>
        <zip>L6J 7W5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JRB Research Inc.</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 7X3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Toronto</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4W 2N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>K. Papp Clinical Research Inc.</name>
      <address>
        <city>Waterloo</city>
        <state>Ontario</state>
        <zip>N2J 1C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Innovaderm Research Inc. - Clinic</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2X 2V1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint-André - Chu de Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <state>Nouvelle-aquitaine</state>
        <zip>33075</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint-Louis - Gh de La Rochelle</name>
      <address>
        <city>La Rochelle</city>
        <state>Nouvelle-aquitaine</state>
        <zip>17000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Hotel Dieu - Chu de Nantes</name>
      <address>
        <city>Nantes</city>
        <state>PAYS DE LA Loire</state>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital La Timone-Dermatologie</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Louis, Centre de Santé Sabouraud</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vita Longa Sp.Zo.O</name>
      <address>
        <city>Katowice</city>
        <zip>40-748</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SGD S.C.</name>
      <address>
        <city>Krakow</city>
        <zip>31-147</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>My Clinic</name>
      <address>
        <city>Warsaw</city>
        <zip>00-144</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royalderm Agnieszka Nawrocka</name>
      <address>
        <city>Warsaw</city>
        <zip>02-962</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Y Provincial de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>8036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. U. Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 16, 2020</study_first_submitted>
  <study_first_submitted_qc>August 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 19, 2020</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alopecia</keyword>
  <keyword>Hair loss</keyword>
  <keyword>Hair disease</keyword>
  <keyword>CTP-543</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alopecia</mesh_term>
    <mesh_term>Alopecia Areata</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

